Matthew Gline Biography and Net Worth

CEO of Roivant Sciences

Matt Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy.

Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.

What is Matthew Gline's net worth?: The estimated net worth of Matthew Gline is at least $186.57 million as of September 23rd, 2024. Mr. Gline owns 17,870,543 shares of Roivant Sciences stock worth more than $186,568,469 as of March 27th. This net worth estimate does not reflect any other investments that Mr. Gline may own. Additionally, Mr. Gline receives a salary of $1,770,000.00 as CEO at Roivant Sciences. Learn More about Matthew Gline's net worth.
How old is Matthew Gline?: Mr. Gline is currently 40 years old. There are 5 older executives and no younger executives at Roivant Sciences. Learn More on Matthew Gline's age.
What is Matthew Gline's salary?: As the CEO of Roivant Sciences Ltd., Mr. Gline earns $1,770,000.00 per year. Learn More on Matthew Gline's salary.
How do I contact Matthew Gline?: The corporate mailing address for Mr. Gline and other Roivant Sciences executives is Clarendon House, 2 Church Street, Hamilton Parish HM 11. Roivant Sciences can also be reached via phone at 44-20-7400-3347 and via email at ir@roivant.com. Learn More on Matthew Gline's contact information.
Has Matthew Gline been buying or selling shares of Roivant Sciences?: Matthew Gline has not been actively trading shares of Roivant Sciences during the last quarter. Most recently, Matthew Gline sold 1,983,257 shares of the business's stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $11.79, for a transaction totalling $23,382,600.03. Following the completion of the sale, the chief executive officer now directly owns 17,870,543 shares of the company's stock, valued at $210,693,701.97. Learn More on Matthew Gline's trading history.
Who are Roivant Sciences' active insiders?: Roivant Sciences' insider roster includes Matthew Gline (CEO), Rakhi Kumar (CAO), Keith Manchester (Director), Mayukh Sukhatme (President and Chief Investment Officer), and Eric Venker (COO). Learn More on Roivant Sciences' active insiders.
Are insiders buying or selling shares of Roivant Sciences?: In the last year, Roivant Sciences insiders bought shares 1 times. They purchased a total of 16,845,010 shares worth more than $336,900,200.00. In the last year, insiders at the sold shares 18 times. They sold a total of 6,815,479 shares worth more than $79,086,208.08. The most recent insider tranaction occured on March, 24th when COO Eric Venker sold 434,478 shares worth more than $4,701,051.96. Insiders at Roivant Sciences own 7.9% of the company. Learn More about insider trades at Roivant Sciences.
Information on this page was last updated on 3/24/2025.

Matthew Gline Insider Trading History at Roivant Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/23/2024	Sell	1,983,257	$11.79	$23,382,600.03	17,870,543
10/25/2022	Sell	19,276	$4.40	$84,814.40	1,164,009
9/23/2022	Sell	21,053	$3.07	$64,632.71	1,183,285
8/24/2022	Sell	20,009	$3.71	$74,233.39	1,204,338
7/25/2022	Sell	20,455	$4.33	$88,570.15	1,224,347
6/23/2022	Sell	19,855	$4.34	$86,170.70	1,244,802
5/20/2022	Sell	139,791	$3.70	$517,226.70	1,264,657
4/25/2022	Sell	8,509	$3.84	$32,674.56	1,404,448
3/30/2022	Sell	33,686	$4.84	$163,040.24
3/25/2022	Sell	35,386	$5.06	$179,053.16
3/18/2022	Sell	82,006	$5.13	$420,690.78
3/7/2022	Sell	92,324	$5.52	$509,628.48

Matthew Gline Buying and Selling Activity at Roivant Sciences

Roivant Sciences Company Overview

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Today's Range

Now: $10.44

$10.42

$10.70

50 Day Range

MA: $10.77

$10.17

$11.37

2 Week Range

Now: $10.44

$9.96

$13.06

Volume

5,692,193 shs

Average Volume

5,648,278 shs

Market Capitalization

$7.45 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Matthew Gline Biography and Net Worth

What is Matthew Gline's net worth?

How old is Matthew Gline?

What is Matthew Gline's salary?

How do I contact Matthew Gline?

Has Matthew Gline been buying or selling shares of Roivant Sciences?

Who are Roivant Sciences' active insiders?

Are insiders buying or selling shares of Roivant Sciences?